Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3,4-Methylenedioxy-N-isopropylamphetamine (MDI-P, MDIP, MDIPA) is a psychoactive compound belonging to the phenethylamine and substituted amphetamine chemical classes. It is the N-isopropyl analogue of 3,4-methylenedioxyamphetamine (MDA). First synthesized by Alexander Shulgin, MDI-P has been investigated for its potential therapeutic effects in conditions such as HIV infection and cystic fibrosis. In vitro studies have demonstrated potent anti-HIV activity with effectiveness in killing HIV in cell culture. There are also reports of mild analgesic activity in animal models. However, very little is known about its pharmacology, pharmacokinetics, clinical effects or toxicity in humans[1][2][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,4-methylenedioxy-N-isopropylamphetamine.